Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
|ClinicalTrials.gov Identifier: NCT01131208|
Recruitment Status : Completed
First Posted : May 26, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in patients with diffuse large B-cell lymphoma treated with combination chemotherapy with or without rituximab.
|Condition or disease||Intervention/treatment|
|Lymphoma||Genetic: gene expression analysis Other: laboratory biomarker analysis|
- To identify genes predictive of clinical outcome (failure-free survival and overall survival) among patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP induction on ECOG-E4494 using the nuclease protection assay for measuring gene expression in paraffin-embedded tissue.
- To identify genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy.
OUTLINE: This is a multicenter study.
Unstained formalin-fixed, paraffin-embedded samples are analyzed for gene expression via nuclease protection assay.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||Gene Expression Profiling Using Paraffin-embedded Tissues and the Nuclease Protection Assay in Diffuse Large B-cell Lymphoma (DLBCL) Treated With CHOP or R-CHOP: An ECOG and SWOG Correlative Study of E4494|
|Actual Study Start Date :||April 21, 2010|
|Primary Completion Date :||August 21, 2010|
|Study Completion Date :||August 21, 2010|
- Identification of genes predictive of clinical outcome [ Time Frame: 1 month ]
- Identification of genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01131208
|Principal Investigator:||Jane N. Winter, MD||Robert H. Lurie Cancer Center|